BCTX - BriaCell stock rises on license deal for anti-cancer agent

• BriaCell Therapeutics ( NASDAQ: BCTX ) stock rose 5% on Aug. 4 after the company said it secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent to treat cancer.
• In animal models, sCD80 was well-tolerated and stopped tumor growth by potentially restoring natural anti-tumor immunity, BriaCell said in an Aug. 4 press release.
• Under the agreement, BriaCell gains worldwide rights to develop and sell sCD80, while UMBC retains ownership of the patents.
• BriaCell will pay royalties to UMBC upon sale of the product plus patent management costs.
• "Based on the promising data in animal studies, we plan to explore the potential use of sCD80 technology as a therapeutic agent in combination with our other immunotherapies or on its own," said BriaCell's President and CEO Bill Williams.

For further details see: